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This report focuses on epidemiological and clinical features of dengue fever (DF) in Tuscany (Italy) between 2006 and 2012.
Sixty-one DF cases were diagnosed, 32 of which were in the period of Aedes albopictus activity. Some clinical (arthralgia/myalgia,
nausea/vomiting, and skin rash), laboratory (leukopenia and thrombocytopenia), and epidemiological characteristics (travel in a
continent other than Africa) significantly distinguished DF cases from other febrile illnesses. Our data stress the importance of
increasing awareness on dengue in Italy among clinicians in order to reach an early diagnosis in returning travelers and to implement
appropriate clinical and public health interventions.
Dengue fever (DF) is distributed widely in tropicaland subtropical countries with an estimated range
from 50 to over 200 million cases per year.1,2 DF is
caused by four serotypes of the dengue virus (DENV)
and is transmitted by Aedes spp. mosquitoes. DF often
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presents itself as a short, self-limiting viral disease or
may even be asymptomatic. However, in about 1% of
cases DF can progress to a severe clinical form with
hemorrhagic manifestations, plasma leakage, severe
involvement of organs, shock, and death.3 Imported
cases of DF in travelers returning from endemic coun-
tries have been frequently reported in Europe in recent
years.4 Moreover, in 2010, autochthonous cases have
been reported in France and Croatia. This was the first
instance of locally acquired cases since the last Euro-
pean outbreak in Greece between 1927 and 1928.5,6 In
addition, a large epidemic of DF was recently observed
in the Portuguese island of Madeira.7
The risk of emergence of autochthonous cases is
related to the presence of competent vector mosquitoes
such as Aedes albopictus and Aedes aegypti in European
territories. Aedes albopictus is present in 20 European
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countries, among which Italy is the most heavily
infested.8 Aedes aegypti, the most effective DENV
vector,9 is present in Europe, but currently limited to
Madeira, few countries around the Black Sea (southern
Russia, Abkhazia, and Georgia), and the Netherlands.8
The diagnosis of fever in returned travelers may
be challenging and, after excluding malaria, prompts
the physician to consider a wide range of diseases
and diagnostic tests. The main purpose of this study
was to increase awareness of dengue in Italy among
clinicians, who are advised to request diagnostic tests
for suspected cases and report confirmed cases to public
health authorities in order to implement vector control
measures as required. We report the results of a retro-
spective study carried out with the aim of (1) describing
epidemiological, clinical, and laboratory characteristics
of DF cases observed in Tuscany region of Italy and
(2) comparing data on laboratory-confirmed dengue
(LCD) to suspected DF patients with negative serolog-
ical test results for DF, who were classified as cases of
other febrile illnesses (OFI).
Patients and Methods
The study was promoted by the Tuscan Reference Cen-
tre for Tropical Diseases (TRCTD) and proposed to
include all infectious diseases units (n= 11) of Tus-
cany. Ten infectious diseases units from eight of nine
provinces agreed to participate.
The TRCTD laboratory provides diagnostic sup-
port for some tropical diseases such as DF to other
Tuscan health facilities. Serological tests for DF
available at TRCTD are: (1) Dengue IgG Capture
ELISA, Panbio Diagnostics (Brisbane, Australia); (2)
Dengue IgM Capture ELISA, Panbio Diagnostics;
and (3) Platelia Dengue NS1 Ag assay (EIA), Bio-Rad
Laboratories (Marnes la Coquette, France). For this
study, serological criteria for LCD cases were defined
as presence of anti-DENV IgM antibodies and/or
positivity for NS1 antigen. Epidemiological, clinical,
and laboratory characteristics of patients with LCD
diagnosed in the period 2006 to 2012 were collected
retrospectively by reviewing medical records. More-
over, the LCD cases observed in the period 2006
to 2010 were then compared with patients classified
with OFI. For the second aim, the exclusion criteria
concerning both LCD and OFI patients were: (1)
cases without available clinical data; (2) positivity for
dengue IgG only; (3) single dengue IgG and dengue
IgM negative result on tests performed during the
first 4 days from onset of symptoms; (4) patients diag-
nosed with malaria; and (5) patients whose onset of
fever was >15 days after return from travel. Malaria
was excluded considering that any returned traveler
with fever is assumed to have malaria unless proven
otherwise; hence parasitological exams are performed
before any other laboratory diagnostic test. The statis-
tical analysis compared categorical variables between
the two groups, LCD and OFI, using chi-square
and Fisher’s exact test when appropriate. Odds ratio
(OR) was also evaluated for variables with p< 0.05
(Table 1).
Results
A total of 61 LCD cases were confirmed in Tuscany
in the period 2006 to 2012. Stratification of the 61
cases by province revealed that 32 cases were observed
in Florence, 10 in Arezzo, 6 in Leghorn, 3 in Lucca,
3 in Grosseto, 3 in Siena, 2 in Pistoia, and 2 in
Massa-Carrara. According to the year of diagnosis, 2
cases were observed in 2006, 5 in 2007, 8 in 2008, 8 in
2009, 15 in 2010, 12 in 2011, and 11 in 2012.
Neither autochthonous nor severe cases of DF were
diagnosed. Information concerning the origin of infec-
tion was available for 51 patients. A total of 30 LCD
cases (58.8%) were acquired in Asia, 11 (21.5%) in Cen-
tral America, 7 (13.7%) in South America, 2 (3.9%) in
Oceania, and 1 (1.9%) in Africa. In regard to the date
of diagnosis, 32 cases (52.4%) were diagnosed in the
period of A. albopictus activity, which is between June
15 and November 30, according to the Italian Min-
istry of Health.10 In the comparison between LCD and
OFI cases in the period 2006 to 2010, samples from 193
patients were tested for suspected DF at the TRCTD.
Among them, 90 were excluded (49OFI and 2 LCDhad
no available clinical data, 23 had fever onset >15 days
after return, 9 had only IgG positivity, 5 were IgG and
IgM negative in the first 4 days after onset of symp-
toms and follow-up samples were not available, and 2
patients had malaria). A total of 36 LCD cases were
observed, accounting for 19% of tested subjects. Of
those, 17 were IgG positive/IgM positive, 15 IgG nega-
tive/IgM positive, 2 NS1Ag positive/IgG negative/IgM
negative, 1 NS1Ag positive/IgG positive/IgM nega-
tive, and 1 NS1Ag positive/IgG positive/IgM positive.
The comparison of epidemiological, clinical, and lab-
oratory characteristics of LCD versus OFI is reported
in Table 1. As far as epidemiological features are con-
cerned, males (p= 0.015; OR: 3.1), traveling to visit fam-
ily/friends (p= 0.046; OR: 3.8) and travel in a continent
other than Africa (p< 0.001; OR: 20.8) were more com-
mon in LCDpatients rather thanOFI patients. For clin-
ical features, arthralgia/myalgia (p= 0.0006; OR: 4.4),
nausea/vomiting (p= 0.0024; OR: 3.6), and skin rash
(p< 0.0001; OR: 15.2) was more common in patients
with LCD. In terms of laboratory findings, LCD
patients most commonly had leukopenia (p< 0.001; OR:
9.8) and thrombocytopenia (p< 0.001; OR: 16.7).
Discussion
After malaria, DF is the second-most common diag-
nosis made on febrile patients returning from tropi-
cal areas and a test for DF must always be included
in the diagnostic work-up in such subjects.4 Physicians
who manage febrile, returning travelers must always
place priority on the differential diagnosis of conditions
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Table 1 Clinical, demographic, and epidemiological features of patients with laboratory-confirmed dengue (LCD) fever and
other febrile illness (OFI) observed in Tuscany (Italy) in the period 2006 to 2010
LCD (N = 36) OFI† (N = 67) p Value*
Demographic features
Male gender 29 (80.5%) 38 (57%) 0.01
OR: 3.1 (95% CI: 1.215 to 8.228)
Female gender 7 (19.5%) 29 (43%) 0.01
OR: 0.3 (95% CI: 0.122 to 0.823)
Age in years: median (range) 39 (21–72) 28 (70–16)
Age in years: mean 40 37.5
Onset after return
Days: median (range) 1 (−17 to 7) 1 (−18 to 14)
Onset after return
Days: mean 4.02 1.8
Country of origin
Italy 31 (86.1%) 58 (86.5%) 1.00
European countries other than Italy 0 3 (4.4%) 0.54
Central America 0 2 (2.9%) 0.54
Latin America 1 (2.8%) 1 (1.4%) 1.00
Oceania 1 (2.8%) 0 0.34
Africa 2 (5.5%) 0 0.11
Asia 1 (2.8%) 3 (4.4%) 1.00
Travel destinations
Asia 18 (50%) 21 (31.3%) 0.06
Central America 10 (27.8%) 11 (16.4%) 0.17
South America 5 (13.9%) 10 (14.9%) 1.00
Oceania 2 (5.5%) 0 0.11
Africa 1 (2.8%) 25 (37.3%) <0.01
OR: 0.6 (95% CI: 0.00 to 0.52)
Continent other than Africa 35 (97.2%) 42 (62.7%) <0.01
OR: 20.8 (95% CI: 2.68 to161.58)
Reason of travel
Business 5 (13.9%) 9 (13.4%) 1.00
Tourism 23 (63.9%) 52 (77.6%) 0.13
Family 7 (19.4%) 4 (5.9%) 0.04
OR: 3.8 (95% CI: 1.03 to14.01)
Others 1 (2.8%) 2 (2.9%) 1.00
Clinical presentation
Headache 15 (41.7%) 25 (37.3%) 0.66
Arthralgia/myalgia 23 (63.9%) 19 (28.3%) <0.01
OR: 4.4 (95% CI: 1.88 to 10.59)
Nausea/vomiting 23 (63.9%) 22 (32.8%) <0.01
OR: 3.6 (95% CI: 1.54 to 8.46)
Mucosal bleeding/petechiae 2 (5.5%) 0 0.11
Rash 15 (41.7%) 3 (4.4%) <0.01
OR: 15.2 (95% CI: 4.01 to 57.84)
Cough/pharyngitis 6 (16.7%) 13 (19.4%) 0.79
Urinary symptoms 1 (2.8%) 3 (4.4%) 1.00
YF, JE, TBE vaccinated 3 (8.3%) 7/45 (15.5%) 0.49
Laboratory findings
Leukopenia (white blood cell <4,000/μL) 24 (66.7%) 10/59 (16.9%) <0.01
OR: 9.8 (95% CI: 3.71 to 25.87)
Thrombocytopenia (platelet counts <150,000/μL) 26 (72.2%) 8/59 (13.5%) <0.01
OR: 16.7 (95% CI: 5.84 to 47.02)
OR= odds ratio; YE = yellow fever; JE = Japanese encephalitis; TBE = tick-borne encephalitis.
*p Value has been determined by chi-square and Fisher’s exact test when appropriate.
†OFI (42 undiagnosed fever in returning traveler, 5 pneumonia, 4 meningitis, 3 urinary tract infection, 3 bacterial sepsis, 2 Epstein–Barr virus (EBV) acute infection, 2
paratyphoid fever, 1 cytomegalovirus (CMV) acute infection, 1 rickettsiosis, 1 pulmonary tuberculosis, 1 amebic dysentery, 1 measles, 1 visceral leishmaniasis).
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that are treatable, that may cause serious sequelae or
death, and pose a risk to public health.11 DF fulfills
all the mentioned priority conditions. Severe DF has
a fatality rate as high as 20% in absence of appropri-
ate medical intervention.12 Although a direct antiviral
for DENV is currently unavailable, supportive ther-
apy for the management of DF improves the out-
come in the affected patients, if strictly implemented,
by reducing the fatality to 1%.12 Moreover, avoidance
of nonsteroidal anti-inflammatory drugs and invasive
procedures is recommended to prevent severe and
even fatal hemorrhagic complications.13 From the pub-
lic health point of view, a subject returning from a
DF-endemic area represents a risk for the emergence
of autochthonous cases in areas where competent vec-
tors are present. All patients included in this study
were febrile from <15 days and were returning from
a dengue-endemic area. As reported in other studies
conducted in Europe, DF is more often diagnosed in
adult male tourists returning from Asia, particularly
Thailand and India, or Central and South America,
mainly from Brazil.12 In three cases, acute DF was diag-
nosed by NS1 antigen detection, providing supportive
evidence that this test is a valid tool for early diag-
nosis of dengue in travelers returning from endemic
areas.14 In our series, three key clinical features (arthral-
gia/myalgia, nausea/vomiting, and skin rash), two labo-
ratory results (leukopenia and thrombocytopenia), and
one epidemiological feature (travel in a continent other
than Africa) significantly distinguished LCD from OFI,
as previously reported.15 In addition, about 52% of
dengue cases were diagnosed in the period of A. albopic-
tus activity. As A. albopictus is present widely in Tuscany,
the reported dengue cases led to implementation of the
regional surveillance program for arthropod-borne dis-
eases that is based on home isolation and pest control
methods around the patient’s house.10,16
This study however has a number of limitations. It
was based on retrospectively collected data, included
only febrile subjects evaluated at infectious diseases
departments, and does not provide information on
serotype as reverse-transcriptase polymerase chain reac-
tion (RT-PCR) was not performed. Moreover, the pres-
ence of anti-DENV IgM antibodies in a single specimen
as a criterion to define a confirmed DF case, although
coupled with clinical and epidemiological informa-
tion, does not completely rule out the possibility of a
false-positive result.
In conclusion, awareness of the main epidemiologi-
cal and clinical features of DF may help physicians to
recognize DF early on and diagnose the same in febrile
travelers from DF-endemic areas.3,13 An appropriate
diagnostic approach is crucial to limit the risk of intro-
duction and transmission of dengue virus in areas where
A. albopictus or A. aegypti are present and in their period
of activity. A rapid identification of an imported DF case
would allow for implementation of adequate control
measures aimed at preventing local transmission. Fur-
thermore, travelers may act as sentinels for providing
information regarding the emergence or reemergence
of DF in a region.
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